Literature DB >> 21381911

The use of stem cells for the repair of cardiac tissue in ischemic heart disease.

Christoph Brenner1, Wolfgang-M Franz.   

Abstract

Ischemic heart diseases are the leading cause of death in the Western world. With increasing numbers of patients surviving their acute myocardial infarction owing to effective heart catheter techniques and intensive care treatment, congestive heart failure has become an increasing health concern. With therapeutic options for the prevention and treatment of ischemic heart disease being limited at present, huge efforts have been made in the field of stem cell research to try to establish new approaches for myocardial tissue regeneration. Owing to their pronounced differentiation potential, pluripotent stem cells seem to represent the most promising cell source for future engineering of myocardial replacement tissue. However, several crucial hurdles regarding cell yield and purity of the cultured cardiovascular progenitor cells have still not been overcome to facilitate a clinical application today. By contrast, plenty of adult stem and progenitor cells have already been well characterized and investigated in human disease. However, all of these heterogeneous cell lines primarily seem to work in a paracrine manner on ischemic myocardial tissue, rather than transdifferentiating into contractile cardiomyocytes. This article will focus on the production, application and present limitations of stem cells potentially applicable for myocardial repair.
© 2011 Expert Reviews Ltd

Entities:  

Mesh:

Year:  2011        PMID: 21381911     DOI: 10.1586/erd.10.78

Source DB:  PubMed          Journal:  Expert Rev Med Devices        ISSN: 1743-4440            Impact factor:   3.166


  3 in total

1.  CX43 change in LPS preconditioning against apoptosis of mesenchymal stem cells induced by hypoxia and serum deprivation is associated with ERK signaling pathway.

Authors:  Jun Wang; Zhi Li; Yangyang Zhang; Xiang Liu; Liang Chen; Yijiang Chen
Journal:  Mol Cell Biochem       Date:  2013-05-28       Impact factor: 3.396

2.  Differentiation of Bone Marrow Mesenchymal Stem Cells to Cardiomyocyte-Like Cells Is Regulated by the Combined Low Dose Treatment of Transforming Growth Factor-β1 and 5-Azacytidine.

Authors:  Shutian Shi; Xingxin Wu; Xiao Wang; Wen Hao; Huangtai Miao; Lei Zhen; Shaoping Nie
Journal:  Stem Cells Int       Date:  2015-11-30       Impact factor: 5.443

3.  DMPE-PEG scaffold binding with TGF-β1 receptor enhances cardiomyogenic differentiation of adipose-derived stem cells.

Authors:  Fei Zhang; Yuan Xie; Yuhao Bian
Journal:  Stem Cell Res Ther       Date:  2018-12-29       Impact factor: 6.832

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.